Diplomat Pharmacy (DPLO) Misses Q3 EPS by 22c, Updates Guidance

Diplomat Pharmacy (NYSE: DPLO) reported Q3 EPS of $0.00, $0.22 worse than the analyst estimate of $0.22. Revenue for the quarter came in at $1.37 billion versus the consensus estimate of $1.42 billion.

GUIDANCE:

Diplomat Pharmacy sees 2018 EPS of ($0.10)-$0.03, versus the consensus of $0.83. Diplomat Pharmacy sees 2018 revenue of $5.5-5.7 billion, versus the consensus of $5.64 billion.

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• Globant (GLOB) Misses Q2 EPS by 10c, Offers Guidance
• Veritone (VERI) Misses Q2 EPS by 13c ; Offers Guidance
• Cadrenal Therapeutics, Inc. (CVKD) Tops Q2 EPS by 27c